FIG. 2.
Analysis of IRF-3 and NF-κB in RRV-infected cells. (A) MA104 cells were either mock infected or infected with RRV at an MOI of 1 and processed for immunofluorescence at 6 hpi with anti-RRV VP6 (green) and anti-IRF-3 (red). (B) Similarly, mock-infected (M) or infected (I) MA104 cells were lysed at 6 hpi and analyzed by Western blotting using anti-RRV serum (upper panel, positions of the viral proteins are indicated at the right), anti-IRF-3 (middle panel), and antiactin (lower panel). (C) MEF cells were either mock infected or infected with RRV or with rSFV-EGFP (both at an MOI of 1) and processed for immunofluorescence at 6 hpi with anti-RRV VP6 (green) or EGFP (green) and anti-IRF-3 (red). (D) Similarly, mock-infected (M) or infected (I) MEFs were lysed at 6 hpi and analyzed by Western blotting using anti-RRV (upper panel, positions of the viral proteins and a murine protein reacting nonspecifically with the serum [*]) are indicated at the right), anti-IRF-3 (middle panel), and antiactin (lower panel) sera. (E) MEF cells were either mock infected or infected with RRV or rSFV-EGFP at an MOI of 1 and processed for immunofluorescence at 6 hpi with anti-RRV VP6 (green) or EGFP (green) and anti-NF-κB p65 (red). (F) Type I IFN production by MEFs and mDCs in response to RRV at 4, 10, and 24 hpi as determined by a bioassay is shown.